Swimming with sharks: Tekmira CEO comments on Ebola R&D challenge; Cytori raising $13.5M;

@FierceBiotech: New special report: Top 7 life sciences public investors. Feature | Follow @FierceBiotech

@JohnCFierce: BIA did a report on bio-fundraising in the U.K. Hard to see where the promo ends and the analysis begins. Very Yank. More | Follow @JohnCFierce

@DamianFierce:  | Follow @DamianFierce

@EmilyMFierce: Hmmm... Cancer tumours destroyed by berry found in Queensland rainforest. More from The Guardian | Follow @EmilyMFierce

> In an interview, Tekmira ($TKMR) CEO Mark Murray said that developing a therapy for Ebola is like swimming in "shark-infested water." Story

> San Diego-based Cytori Therapeutics is raising $13.5 million through a direct offering. Release

> Israel's BrainStorm Therapeutics says it gained fast-track status at the FDA for its adult stem cell therapy for ALS. Story

Medical Device News

@FierceMedDev: This week's issue of FierceDiagnostics is out! Sign up for free here. | Follow @FierceMedDev

@VarunSaxena2: Flowonix submits MRI-compatible implantable infusion pump for FDA approval. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Robot-assisted surgery often comes with more complications and higher costs, according to new study. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." More | Follow @MichaelGFierce

> At least $200M paid to docs by medical device industry. Item

> Becton plans on $9.1B bridge loan to finance deal with CareFusion. Story

> EU halts distribution of GI Dynamics obesity device. News

> Preview: Boston Scientific's Watchman goes before third FDA panel. More

Pharma News

@FiercePharma: Top-read special report in FP Tues: Top 10 pharma companies by employees - 2014. Feature | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bayer insists its probiotic marketing claims aren't full of hot air. Article | Follow @CarlyHFierce

> Novartis, GSK shake up executive ranks as overhaul continues. Article

> With Actavis poised to swoop in, Valeant eyes $4.5B hike in bid for Allergan. Report

Drug Delivery News

> Flat nanosheets roll drugs up and release them on command. Item

> With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. More

> Flowonix submits MRI-compatible implantable infusion pump for FDA approval. Story

> USPTO to review delivery patent in spat between Suboxone and BDSI's Bunavail. Report

> Alnylam says it wants to enter larger disease areas using partnership-driven approach. More

Diagnostics News

> MD Anderson pursues two projects targeting personalized prostate cancer testing. News

> Health Diagnostic Laboratory helps find promising predictive diabetes biomarkers. More

> Swedes, Harvard and more find success with DNA test for Afib risks. Report

> NanoString and a Harvard-affiliated hospital hope to quicken creation of new cancer tests. Story

> Quest, in transition, recruits Mayo Clinic exec to run major division. Article

Pharma Marketing News

> Analysts: Actavis-Allergan deal could create a marketing superpower. Item

> Pfizer's new #viagracommercial lights up Twitter during MLB playoffs--and not in a good way. More

> Merck hops onto HBCU network to step up its brand in the African-American community. Report

> Hand out prizes for adherence? West and HealthPrize team up to test the idea. Story

> Balking at marketing slapdown, Galderma declares itself pharma non grata. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.